Paul Maertens
Neurology with Special Qualifications in Child Neurology · Mobile, ALNPI 1912951195
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,181 of the $9,697 with a category attached, or 74.1%. 58 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 28.4% of the total. Reporting peaked in 2021 at $2,986 and has fallen 69.4% since, to $915 in 2025.
Across 271 payments — averaging $35.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$3K
- UCB, Inc.$1K
- Jazz Pharmaceuticals Inc.$482
- Sunovion Pharmaceuticals Inc.$449
- SK Life Science, Inc.$446
- Acadia Pharmaceuticals Inc$390
- plus $4K from 52 others
What the payments were for
- Speaking & faculty fees$2,51626%
- Food & beverage$7,18174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,697 in reported general payments places this provider in the 70th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
See all neurology with special qualifications in child neurology providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamictal XrLamotrigine | 13 | $23,953 |
| FelbatolFelbamate | 13 | $23,748 |
| Oxcarbazepine | 54 | $9,450 |
| EliquisApixaban | 15 | $8,264 |
| Lacosamide | 20 | $7,965 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $1,460 |
| Clobazam | 12 | $1,410 |
| Diazepam | 11 | $1,001 |
| Phenobarbital | 24 | $751 |
| Risperidone | 20 | $714 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $646 |
| Baclofen | 15 | $623 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $479 |
| Levetiracetam | 18 | $456 |
| Lamotrigine | 32 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $8,26415 claims |
| Upsher-smith Laboratories LLCTopiramate | $265 | $25518 claims |
| Lilly USA, LLCOlanzapine | $13 | $9612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
Other neurology with special qualifications in child neurology in Mobile
- Asri YuliatiMobile$2K
- Hanan El ShakankiryMobile$329
- April ConsevageMobile$27
- Alyssa ReddyBirmingham$68K
- Alan PercyBirmingham$51K
- Kimberly LimboHuntsville$43K
- Michael LopezBirmingham$22K
- Elizabeth BebinBirmingham$15K
- Amitha AnanthBirmingham$10K
- Ahmad Al-HamdaMuscle Shoals$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.